Ligand Pharmaceuticals (LGND) Revenue (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Revenue data on file, last reported at $51.7 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 14.09% year-over-year to $51.7 million; the trailing twelve-month figure through Mar 2026 stood at $274.5 million (up 51.24% YoY), and the FY2025 full-year result was $268.1 million, up 60.4% from the prior year.
• Revenue retreated to $51.7 million in Q1 2026, from $59.7 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $115.5 million in Q3 2025 to a low of $26.4 million in Q2 2023.
• A 5-year average of $47.9 million and a median of $45.3 million in 2025 frame the typical range for Revenue.
• Across the five-year window, Revenue sank 47.4% in 2023 and surged 122.85% in 2025, its largest moves.
• Tracing LGND's Revenue over 5 years: stood at $50.4 million in 2022, then slumped by 44.22% to $28.1 million in 2023, then soared by 52.35% to $42.8 million in 2024, then soared by 39.37% to $59.7 million in 2025, then slipped by 13.31% to $51.7 million in 2026.
• Business Quant data shows LGND's Revenue at $51.7 million in Q1 2026, $59.7 million in Q4 2025, and $115.5 million in Q3 2025.